Events

Scivil Citizen Science Networking Day 2024
SEP
Thu
12
09:15 - 17:30

This was 1 year ago

Location

Lamot Mechelen

Van Beethovenstraat 8-10
2800 Mechelen
Belgium
Programmes
Enhancing EU R&I SwafS

The Flemish knowledge center for citizen science (Scivil) organizes the Citizen Science Networking Day 2024 in collaboration with FAROHistories and the AfricaMuseum. On the programme are presentations, panel discussions and workshops on a variety of subjects given by citizen science experts, citizen scientists and others whom share their experiences with citizen science projects. During lunch and the reception a poster session takes place (submit a poster).

Half of the sessions are in Dutch and the other half in English. The language is indicated per session on the programme. Participation is free but please take note of the no-show fee (50 euro).

The complete programme and registration form of the Networking Day are available in the announcement on the website of Scivil.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.